Antiviral therapy for chronic hepatitis B in China

作者：Zheng Xin; Wang Junzhong; Yang Dongliang^*

来源：Medical Microbiology and Immunology, 2015, 204(1): 115-120.

DOI：10.1007/s00430-014-0380-z

• Chronic hepatitis B
• Antiviral therapy
• Drug resistance
• China

The vaccination program against hepatitis B virus (HBV) has greatly reduced the incidence of HBV infection. However, almost one-fourth of the HBV infected patients worldwide are still located in China. The healthcare burden from chronic HBV infection is a big challenge for the Chinese government and clinicians. Antiviral therapy plays a central role in controlling chronic HBV infection and preventing the disease progression. However, due to the specific economic and medical system issues, the first-line antiviral agents recommended by the AASLD and EASL have not been widely used for Chinese patients. In this review, we will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China.

• 出版日期2015-2
• 单位华中科技大学